This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Bristol-Myers Squibb says it withdrew US antitrust paperwork for Celgene buy, will refile Feb. 20

( February 20, 2019, 15:11 GMT | Official Statement) -- MLex Summary: Bristol-Myers Squibb said that it has withdrawn antitrust paperwork for its proposed acquisition of Celgene in order to facilite continued dialogue with the US Federal Trade Commission. The company plans to refile notification today, which will restart the 30-day time frame for the FTC’s initial review of the transaction. The transaction remains on track to close in the third quarter of 2019, it said.See full statement below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login